ESSA Pharma Reports Progress in Masofaniten Study
Company Announcements

ESSA Pharma Reports Progress in Masofaniten Study

ESSA Pharma Inc (EPIX) has released an update.

The Company announced new dose escalation data from its Phase 1/2 study of Masofaniten in combination with enzalutamide for treatment in a press release on January 25, 2024, presented at the 2024 ASCO Genitourinary Cancers Symposium.

For further insights into EPIX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskESSA Pharma’s Promising Prostate Cancer Trial Updates
PR NewswireESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
TheFlyEssa Pharma reports Q2 EPS (20c), consensus (19c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!